Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: Pirtobrutinib
DRUG: Ibrutinib
DRUG: Acalabrutinib
DRUG: Zanubrutinib

Sponsor

Loxo Oncology, Inc.

Collaborators

[object Object]